Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Nichols

Showing results (301-310 of 331) with videos related to

Pageof 34
Sort By:
Annals of the American Thoracic Society|September 17, 2025
Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/IvacaftorScott D Sagel, T Spencer Poore, Brandie D Wagner, et al.
Contemporary Clinical Trials|November 18, 2024
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST studyJill Maggs, Gregory S Sawicki, Callie Bacon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 16, 2023
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosisScott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2018
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P Clancy, David P Nichols, et al.
Plos One|May 5, 2022
Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trialSilvia M Caceres, Linda A Sanders, Noel M Rysavy, et al.
Annals of the American Thoracic Society|January 19, 2021
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study DesignNicole Mayer-Hamblett, David P Nichols, Katherine Odem-Davis, et al.
Journal of Diabetes Research|December 22, 2016
Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related DiabetesJ L Taylor-Cousar, J S Janssen, A Wilson, et al.
Lab on a Chip|May 6, 2022
A microfluidic device and instrument prototypes for the detection of <i>Escherichia coli</i> in water samples using a phage-based bioluminescence assayLuis F Alonzo, Troy C Hinkley, Andrew Miller, et al.
BMJ Open|April 15, 2020
Usual care and a self-management support programme versus usual care and a relaxation programme for people living with chronic headache disorders: a randomised controlled trial protocol (CHESS)Shilpa Patel, Felix Achana, Dawn Carnes, et al.
ERJ Open Research|December 3, 2025
Home sputum collection for <i>Aspergillus fumigatus</i> detection in adults with cystic fibrosisGina Hong, Joanna Walsh, Allen Koshy, et al.
Pageof 34

Showing results (301-310 of 331) with videos related to

Sort By:
Pageof 34
Annals of the American Thoracic Society|September 17, 2025
Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/IvacaftorScott D Sagel, T Spencer Poore, Brandie D Wagner, et al.
Contemporary Clinical Trials|November 18, 2024
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST studyJill Maggs, Gregory S Sawicki, Callie Bacon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 16, 2023
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosisScott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2018
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P Clancy, David P Nichols, et al.
Plos One|May 5, 2022
Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trialSilvia M Caceres, Linda A Sanders, Noel M Rysavy, et al.
Annals of the American Thoracic Society|January 19, 2021
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study DesignNicole Mayer-Hamblett, David P Nichols, Katherine Odem-Davis, et al.
Journal of Diabetes Research|December 22, 2016
Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related DiabetesJ L Taylor-Cousar, J S Janssen, A Wilson, et al.
Lab on a Chip|May 6, 2022
A microfluidic device and instrument prototypes for the detection of <i>Escherichia coli</i> in water samples using a phage-based bioluminescence assayLuis F Alonzo, Troy C Hinkley, Andrew Miller, et al.
BMJ Open|April 15, 2020
Usual care and a self-management support programme versus usual care and a relaxation programme for people living with chronic headache disorders: a randomised controlled trial protocol (CHESS)Shilpa Patel, Felix Achana, Dawn Carnes, et al.
ERJ Open Research|December 3, 2025
Home sputum collection for <i>Aspergillus fumigatus</i> detection in adults with cystic fibrosisGina Hong, Joanna Walsh, Allen Koshy, et al.
Pageof 34